<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4783">
  <stage>Registered</stage>
  <submitdate>7/08/2012</submitdate>
  <approvaldate>7/08/2012</approvaldate>
  <nctid>NCT01661101</nctid>
  <trial_identification>
    <studytitle>Management of Myocardial Injury After Noncardiac Surgery Trial</studytitle>
    <scientifictitle>A Large, International, Randomized, Placebo-controlled Trial to Assess the Impact of Dabigatran (a Direct Thrombin Inhibitor) and Omeprazole (a Proton-pump Inhibitor) in Patients Suffering Myocardial Injury After Noncardiac Surgery</scientifictitle>
    <utrn />
    <trialacronym>MANAGE</trialacronym>
    <secondaryid>2011-006056-37</secondaryid>
    <secondaryid>1160.143</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Myocardial Injury After Noncardiac Surgery (MINS)</healthcondition>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Other skin conditions</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Dabigatran
Treatment: drugs - Placebo (for Dabigatran)
Treatment: drugs - Omeprazole
Treatment: drugs - Placebo (for Omeprazole)

Experimental: Dabigatran - Dabigatran 110 mg capsule taken twice daily

Experimental: Omeprazole - Omeprazole 20 mg capsule taken once daily

Placebo Comparator: Placebo (dabigatran) - Dabigatran placebo taken twice daily

Placebo Comparator: Placebo (omeprazole) - Omeprazole placebo taken once daily


Treatment: drugs: Dabigatran
Dabigatran 110 mg taken twice daily

Treatment: drugs: Placebo (for Dabigatran)
Dabigatran placebo taken twice daily

Treatment: drugs: Omeprazole
Omeprazole 20 mg capsule taken once daily

Treatment: drugs: Placebo (for Omeprazole)
Omeprazole placebo taken once daily

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Major vascular complication (for Dabigatran) - A composite of the number of patients suffering vascular mortality, nonfatal myocardial infarction, nonfatal stroke, nonfatal peripheral arterial thrombosis, and nonfatal symptomatic pulmonary embolism.</outcome>
      <timepoint>Average of 1 year follow-up</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Major upper gastrointestinal complication (for Omeprazole) - A composite of the number of patients suffering overt gastroduodenal bleeding, overt upper gastrointestinal bleeding of unknown origin, or upper gastrointestinal perforation.</outcome>
      <timepoint>Average of 1 year follow-up</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Individual secondary outcomes for Dabigatran - The number of patients suffering all-cause mortality, vascular mortality, myocardial infarction, stroke, cardiac revascularization procedure, symptomatic venous thromboembolism (i.e., symptomatic pulmonary embolism or symptomatic deep venous thrombosis), amputation, peripheral arterial thrombosis, and rehospitalization for vascular reasons.</outcome>
      <timepoint>Average of 1 year follow-up</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Upper gastrointestinal complication for Omeprazole - A composite of the number of patients suffering overt gastroduodenal bleeding, overt upper gastrointestinal bleeding of unknown origin, symptomatic gastroduodenal ulcer, gastrointestinal pain with underlying multiple gastroduodenal erosions, or upper gastrointestinal perforation.</outcome>
      <timepoint>Average of 1 year follow-up</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Major vascular complication for Omeprazole - A composite of the number of patients suffering vascular mortality, nonfatal myocardial infarction, nonfatal stroke, nonfatal peripheral arterial thrombosis and nonfatal symptomatic pulmonary embolism.</outcome>
      <timepoint>Average of 1 year follow-up</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Individual secondary outcomes for Omeprazole - The number of patients suffering overt gastroduodenal bleeding, overt esophageal bleeding, overt upper gastrointestinal bleeding of unknown origin, symptomatic gastroduodenal ulcer, gastrointestinal pain with underlying multiple gastroduodenal erosions, upper gastrointestinal perforation, and bleeding of assumed occult gastrointestinal origin with a documented drop in hemoglobin of = 3.0 g/dL.</outcome>
      <timepoint>Average of 1 year follow-up</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety outcomes for Dabigatran - The number of patients suffering life-threatening bleeding, major bleeding, intracranial bleeding, minor bleeding, significant lower gastrointestinal bleeding, non-significant lower gastrointestinal bleeding, and dyspepsia.</outcome>
      <timepoint>Average of 1 year follow-up</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety outcomes for Omeprazole - The number of patients suffering Clostridium difficile-associated diarrhea, diarrhea, community-acquired pneumonia, and fractures.</outcome>
      <timepoint>Average of 1 year follow-up</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients are eligible if they:

          1. have undergone noncardiac surgery;

          2. are =45 years of age;

          3. have suffered MINS based upon fulfilling one of the following criteria: A. Elevated
             troponin or CK-MB measurement with one or more of the following defining features i.
             ischemic signs or symptoms (i.e., chest, arm, neck, or jaw discomfort; shortness of
             breath, pulmonary edema); ii. development of pathologic Q waves present in any two
             contiguous leads that are =30 milliseconds; iii. electrocardiogram (ECG) changes
             indicative of ischemia (i.e., ST segment elevation [=2 mm in leads V1, V2, or V3 OR =1
             mm in the other leads], ST segment depression [=1 mm], OR symmetric inversion of T
             waves =1 mm) in at least two contiguous leads; iv. new LBBB; or v. new or presumed new
             cardiac wall motion abnormality on echocardiography or new or presumed new fixed
             defect on radionuclide imaging B. Elevated troponin measurement after surgery with no
             alternative explanation (e.g., pulmonary embolism, sepsis) to myocardial injury; AND

          4. provide written informed consent to participate within 35 days of suffering their
             MINS.</inclusivecriteria>
    <inclusiveminage>45</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Patients meeting any of the following criteria will be excluded:

          1. hypersensitivity or known allergy to dabigatran;

          2. history of intracranial, intraocular, or spinal bleeding;

          3. hemorrhagic disorder or bleeding diathesis;

          4. known hepatic impairment or liver disease expected to have an impact on survival;

          5. condition that requires therapeutic dose anticoagulation (e.g., prosthetic heart
             valve, venous thromboembolism, atrial fibrillation);

          6. currently using or plan to initiate rifampicin, cyclosporine, itraconazole,
             tacrolimus, ketoconazole, or dronedarone;

          7. women who are pregnant, breastfeeding, or of childbearing potential who refuse to use
             a medically acceptable form of contraception throughout the study;

          8. investigator considers the patient unreliable regarding requirement for study
             follow-up or study drug compliance; OR

          9. previously enrolled in the MANAGE Trial.

        Also excluded will be patients in whom any of the following criteria persist beyond 35 days
        of their suffering MINS:

          1. the attending surgeon believes it is not safe to initiate therapeutic dose
             anticoagulation therapy;

          2. the attending physician believes ASA, intermittent pneumatic compression, or elastic
             stockings are not sufficient for venous thromboembolism (VTE) prophylaxis and that the
             patient requires a prophylactic-dose anticoagulant;

          3. the patient has an indwelling epidural or spinal catheter that cannot be removed, or
             the first dose of dabigatran will occur within 4 hours of epidural catheter removal;
             OR

          4. estimated glomerular filtration rate (eGFR) &lt;35 ml/min as estimated by calculated
             creatinine clearance.

          5. it is expected that the patient will undergo cardiac catheterization for MINS.

        Exclusion Criteria Specific to Patients in the Omeprazole Factorial Component of the Trial:

        Patients meeting any of the following criteria:

          1. hypersensitivity or known allergy to omeprazole;

          2. requirement for a proton pump inhibitor, an H2-receptor antagonist, sucralfate,
             atazanavir, clopidogrel, or misoprostol;

          3. esophageal or gastric variceal disease; OR

          4. patient declines participation in the omeprazole arm of MANAGE.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Factorial</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/01/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>1754</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/03/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Westmead Hospital - Westmead</hospital>
    <postcode>2145 - Westmead</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Buenos Aires</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Santa Fe</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Cordoba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Minas Gerais</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Paraná</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Belo Horizonte</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Campinas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Rio de Janeiro</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>São José do Rio Preto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Manitoba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Colombia</country>
      <state>Santander</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Colombia</country>
      <state>Bogota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Liberec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Motol</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Copenhagen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Herlev</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Hillerød</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Koege</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Vejle</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lyon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hesse</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bonn</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Distt- Ludhiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Gujarat,</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Kerala</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Bangalore</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Bengaluru</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Lucknow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Ludhiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Nagpur</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Tiruvannamalai</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Udine</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Monza</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Kenya</country>
      <state>Nairobi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Peru</country>
      <state>Lima</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Philippines</country>
      <state>Dasmariñas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Philippines</country>
      <state>Manila</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Bochnia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Brzesko</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Krakow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Kraków</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Miechów</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Myslenice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Tarnow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Wloszczowa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Kwazulu-Natal</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Bloemfontein</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Cape Town</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>North Ireland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Dudley</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Population Health Research Institute</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Patients who have myocardial injury after noncardiac surgery are at a higher risk of dying
      than those who do not. One in 10 patients with myocardial injury will die within 30 days of
      surgery. This risk of death exists up to one year after myocardial injury. There are
      currently no treatments or guidelines available for heart injury after surgery, but there is
      evidence that taking a blood-thinner can prevent some of the deaths, both in the short and
      long-term. The purpose of this trial is to test the effect of two drugs (dabigatran and
      omeprazole) that may prevent mortality, major cardiovascular complications and major upper
      gastrointestinal bleeding in patients who have had myocardial injury after noncardiac
      surgery.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01661101</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>P.J. Devereaux, MD, PhD</name>
      <address>Population Health Research Institute</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>